ライフサイエンスコーパス: tail flick

1 ey hair), and thermal sensitivity (hot plate/tail flick).

2 k: 70-75%; jump: 60-81%) and beta-endorphin (tail-flick: 100%; jump: 93%) analgesia elicited from the

3 the PAG significantly reduced both morphine (tail-flick: 70-75%; jump: 60-81%) and beta-endorphin (ta

4 Antinociception studies using a radiant-heat tail flick analgesia method demonstrated that lambda-car

5 hine before norBNI responded strongly in the tail-flick analgesia assay to a subsequent challenge wit

6 eptive responses to morphine measured in the tail-flick analgesia assay.

7 vitro kappa antagonism were confirmed in the tail-flick analgesia model.

8 on of these hodgkinsine stereoisomers in the tail flick and capsaicin pain models are reported.

9 antagonist, on nociceptive responses in the tail flick and formalin tests in mice.

10 knockout mice displayed shorter latencies on tail flick and hot plate tests for spinal and supraspina

11 ueductal gray were determined using both the tail flick and the foot withdrawal responses to noxious

12 were confirmed in the antinociceptive tests (tail-flick and acetic acid writhing) in mice, which demo

13 increased nociceptive responses on both the tail-flick and foot-withdrawal tests.

14 strength, and heat nociception, measured by tail-flick and hindlimb withdrawal tests, were not affec

15 ), for pharmacological activity in the mouse tail-flick and hot-plate assays, and for hypothermia and

16 iled to produce antinociception in the mouse tail-flick and hot-plate assays, engender nicotine-like

17 were markedly diminished in the radiant heat tail-flick and hot-plate assays.

18 ams of CGP 35348 antagonized the increase in tail-flick and hot-plate latency produced by either dose

19 in vivo for antinociception activity in the tail-flick and hot-plate models of acute pain and for th

20 on, 5g was a nicotine antagonist in both the tail-flick and hot-plate tests, whereas 8a was an antago

21 glion neurons, and (3) no change in baseline tail-flick and hotplate reflex nocifensive responses.

22 ormalin test, and the thermal (49 degrees C) tail-flick and increasing-temperature (3 degrees C/min)

23 ine-6beta-glucuronide (M6G) analgesia on the tail-flick and jump tests differed in potency in the per

24 teral periaqueductal gray as measured by the tail-flick and jump tests in rats.

25 25 and 250 nmol and the resulting effects on tail-flick and nociceptive foot-withdrawal latencies wer

26 of a TIP39 antibody decreased sensitivity in tail-flick and paw-pressure assays.

27 prevented tolerance to morphine in both the tail-flick and the formalin test.

28 degrees C hot plate, 52 degrees C warm-water tail-flick and the Hargreaves paw-withdrawal tests.

29 was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with l

30 es to noxious thermal stimulation (hotplate, tail flick) and to persistent noxious chemical stimulati

31 plate, high- and low-intensity radiant heat tail flick, and von Frey hair assays.

32 In the present study, hot-water-immersion tail-flick antinociception assays at 52 degrees C on mic

33 hand, the mutant mice react normally in the tail flick assay and acetic acid-induced writhing tests.

34 In a tail flick assay of nociception, TAL increased response

35 gy between deltaORs and alpha2AARs using the tail flick assay of thermal nociception in mice.

36 there was no difference in the low-intensity tail flick assay.

37 times more potent than morphine in the mouse tail-flick assay (ED(50) = 0.05 mg/kg), and (-)-(1R,5R,

38 a partial agonist effect in the 55 degrees C tail-flick assay and a full agonist effect in the acetic

39 ted by the intrathecal route using the mouse tail-flick assay and binding studies.

40 A warm-water (50 degrees C) tail-flick assay revealed a significant decrease in morp

41 compounds 3a-g and 4 were more potent in the tail-flick assay than the hot-plate test.

42 ater analgesia, as assayed in the warm water tail-flick assay, in NET-knock-out (-KO) mice than in wi

43 In the mouse tail-flick assay, intrathecal (i.t.) NNTA produced antin

44 nism and acted as a potent antagonist in the tail-flick assay.

45 nity and spinal analgesia as measured in the tail-flick assay.

46 teromeric opioid receptors, and in the mouse tail-flick assay.

47 annabinoid agonist CP55,940 (21) in a rodent tail-flick assay.

48 of nicotine-mediated antinociception in the tail-flick assay.

49 type to antagonize nicotine's effects in the tail-flick assay.

50 eption with an ED50 of 0.07 microg/kg in the tail-flick assay.

51 on and increased withdrawal latencies in the tail-flick assay.

52 ed in mice lacking ORL-1 receptors using the tail-flick assay.

53 ociception was measured using a radiant heat tail-flick assay; mechanical sensitivity was measured us

54 cies in the hot plate and the high-intensity tail flick assays (hypoalgesia), but there was no differ

55 harmacological manipulations utilized in our tail-flick assays on GM1-treated mice provide a novel bi

56 (1 mg/kg) (measured by warm-water-immersion tail-flick assays).

57 otency of morphine, as measured by hot-water tail-flick assays.

58 The cold-water tail-flick (CWT) test was used to measure antinociceptio

59 d for antinociceptive activity (55 degrees C tail flick) in mice.

60 00, 300, 600 microg), into the PAG increased tail flick latencies in male and female rats.

61 tar S-DHPG (0.1, 1.0, 10 mM) does not change tail flick latencies or paw withdrawal latencies to heat

62 ive to NMDA antagonism, but not hot plate or tail flick latencies, which were insensitive to NMDA ant

63 clei of the amygdala significantly increased tail-flick latencies and jump thresholds in rats.

64 he OFQ/N fragments in the amygdala increased tail-flick latencies on this measure.

65 WIN55,212-2 significantly elevated tail-flick latencies when injected into the amygdala, th

66 (ED50=30 microg) in significantly increasing tail-flick latencies with longer durations of action.

67 nd time-dependent increase in high-intensity tail-flick latencies with maximal effects observed at a

68 tagonist, did not antagonize the increase in tail flick latency (TFL) produced by microinjection of L

69 activity of compound 5b was evaluated by the tail flick latency test, giving an ED50 of 2.5 mg/kg.

70 BLA resulted in a time dependent increase in tail flick latency that was attenuated by preadministrat

71 dy, the effects of phenylephrine infusion on tail flick latency was determined before and after salin

72 Radiant heat tail flick latency, as a measure of behavioral effects,

73 ndently increased mean arterial pressure and tail flick latency, but had inconsistent effects on neur

74 or 3 mg kg(-1) d(-1) FP15 reversed increased tail-flick latency (a sign of reduced pain sensitivity);

75 or nonpaced) showed significant increases in tail-flick latency (TFL) within 5 s (time 0) after matin

76 iferative responses by 80% and elevated both tail-flick latency and plasma corticosterone when compar

77 Controls showed a pronounced elevation in tail-flick latency following presentation of 90-dB white

78 s, manifested by rapid onset of decreases in tail-flick latency for periods >3 h after drug administr

79 ng-lasting response in rats monitored by the tail-flick latency measurements.

80 antagonists by themselves did not alter the tail-flick latency or the analgesic effect of deltorphin

81 tary-adrenal (HPA) axis and antinociception (tail-flick latency) were examined.

82 ven twice a day for 4 days did not alter the tail-flick latency.

83 40 mg/kg, i.p.) by itself did not alter the tail-flick latency.

84 ory brainstem response (ABR) amplitudes, and tail-flick latency.

85 slightly blocked anti-nociception in a naive tail-flick model, while enhancing morphine-induced preci

86 placements displayed analgesic ED50s on the tail-flick (morphine: 1.4 microgram, M6G: 0.06 microgram

87 placements displayed analgesic ED50s on the tail-flick (morphine: 1.7 microgram, M6G: 0.1 microgram)

88 placements displayed analgesic ED50s on the tail-flick (morphine: 2.1 microgram, M6G: 0.2 microgram)

89 0 g) and antinociception was obtained on the tail flick or foot withdrawal tests.

90 lpha of saline-pretreated rats did not alter tail-flick or hot-plate latency.

91 CART was not active in the tail-flick or PPQ tests.

92 hippocampal infusions had greater analgesia (tail flick, paw lick), less anxiety behavior (plus-maze,

93 began during the 50 msec after onset of the tail flick, peaked within 200 msec, and outlasted the du

94 uation of 1, 2e, and 2f sc in mice using the tail-flick procedure indicated that they are selective d

95 ring associated with the noxious heat-evoked tail flick reflex were used to classify neurons as "on-c

96 the ability of phenylephrine to inhibit the tail flick reflex.

97 of mustard oil and measuring the nociceptive tail-flick reflex in awake rats.

98 pectively, and produced an inhibition of the tail-flick reflex in normal animals.

99 The inhibition of the tail-flick reflex produced by mustard oil following spin

100 ations that eliminated the inhibition of the tail-flick reflex restored vocalization to thermal stimu

101 the hind leg produced a facilitation of the tail-flick reflex that was significantly reduced in spin

102 d mustard oil hyperalgesia and inhibited the tail-flick reflex.

103 persistently suppressed radiant heat-evoked tail flick reflexes of anesthetized rats.

104 In contrast, the increase in the tail flick response latency produced by morphine was red

105 ter of the brain results in an increased rat tail flick response to a painful stimulus.

106 e relationship between the inhibition of the tail-flick response and brain-mediated responses to noci

107 B4101 partially reversed the increase in the tail-flick response latency produced by morphine.

108 ppress multi-segmental reflexes, such as the tail-flick response.

109 gray using both the foot-withdrawal and the tail-flick responses to noxious radiant heating in light

110 an on core body temperature and nociceptive (tail flick) responses.

111 v administration as measured analgesia using tail-flick (spinal involvement) and hot-plate (supraspin

112 nociception in the hotplate; however, in the tail flick test a dose of 2 mg/kg was required for an an

113 .07 and 0.04 microg/kg, respectively, in the tail flick test and only 35 and 0% inhibition at 20 and

114 rkedly increased withdrawal latencies in the tail flick test and reduced responses to subcutaneous fo

115 Rats were tested in the tail flick test before and after microinjections of the

116 ference conditioning for reward effects, the tail flick test for nociception, and a measure of locomo

117 ad no effect on the altered responses in the tail flick test in aged rats, and in general, had no eff

118 increases in antinociceptive responses on a tail flick test in both male and female rats.

119 s (13l and 11b) showed analgesic response in tail flick test which was blocked by pretreatment with n

120 the epibatidine analogues are full agonists (tail flick test) in producing antinociception after intr

121 ) or their combination and their behavior in tail flick test, reflective of spinal antinociception an

122 produced antinociception, assessed using the tail flick test, that lasted more than 60 min.

123 Nociception was measured using the tail flick test.

124 tinociception produced by morphine using the tail flick test.

125 n the dose-response curve to morphine on the tail-flick test (a pain sensitivity assay), suggesting e

126 that CART (55-102) was without effect on the tail-flick test after i.t. injection in mice.

127 ll found Delta9-THC-induced analgesia in the tail-flick test and other behavioral (licking of the abd

128 intrathecally, all produced analgesia in the tail-flick test but only 5a produced analgesia in the ho

129 blocked OFQ/N(1-17)-induced analgesia on the tail-flick test elicited from the amygdala, and whether

130 roventricular (i.c.v.) administration in the tail-flick test in mice.

131 mg/kg, i.p.) produced antinociception in the tail-flick test in sham-operated rats.

132 It is held that the tail-flick test of pain depends on a spinal reflex becau

133 knock-out mice exhibited hyperalgesia in the tail-flick test of thermal nociception.

134 70-fold more effective as antagonists in the tail-flick test versus the hot-plate procedure.

135 ve responses to noxious thermal stimulation (tail-flick test) by both types of anesthetics.

136 rophenyl analogue (5e) (AD50 = 0.0003 in the tail-flick test) was the most potent and selective analo

137 cy of tail withdrawal from radiant heat (the tail-flick test).

138 NSAIDs are inactive in the radiant heat tail-flick test, an assay of moderate to severe pain in

139 t as well as the peak (15 min) effect on the tail-flick test, analgesia elicited by either endomorphi

140 stress-induced analgesia as detected by the tail-flick test, but decreased the potency of the opioid

141 tinociception produced by morphine using the tail-flick test, but not that using the foot-withdrawal

142 tent and long lasting antinociception in the tail-flick test, indicating that 13a was able to permeat

143 In the tail-flick test, intrathecal administration of UK 14,304

144 ayed relatively lower antinociception on the tail-flick test, resulting in significantly increased ED

145 eductions in beta-endorphin analgesia on the tail-flick test.

146 ctions of endomorphin-2, particularly on the tail-flick test.

147 , with antinociception being assessed with a tail-flick test.

148 30-60 min in naltrexone-treated rats on the tail-flick test.

149 eductions in beta-endorphin analgesia on the tail-flick test.

150 s of nicotine-induced antinociception in the tail-flick test.

151 n male Swiss-Webster mice as measured by the tail-flick test.

152 tive effect of morphine determined using the tail-flick test.

153 ic interaction on the jump test, but not the tail-flick test.

154 d antinociception in mice as measured by the tail-flick test.

155 a-endorphin analgesia in the amygdala on the tail-flick test.

156 king nicotine-induced antinociception in the tail-flick test.

157 more pronounced on the jump test than on the tail-flick test.

158 s investigated in rats with the radiant heat tail-flick test.

159 ts, whereas 8a was an antagonist only in the tail-flick test.

160 he antinociceptive effect of morphine in the tail-flick test.

161 ciception was investigated in mice using the tail-flick test.

162 OT did not produce analgesic effects in the tail-flick test.

163 en microinjected into the DRN at the time of tail-flick testing, 8-OH-DPAT also effectively prevented

164 reduce nociceptive responses in hot plate or tail flick tests of homozygous mu receptor knockout mice

165 esently studied in rats on the hot plate and tail flick tests.

166 ose-dependent analgesia in both hotplate and tail-flick tests when administered subcutaneously.

167 mal thermal nociception in the hot-plate and tail-flick tests, and had similar olfactory, auditory an

168 tinociception on both the hot plate (HP) and tail flick (TF) nociceptive tests.

169 to the amygdala results in inhibition of the tail flick (TF) reflex evoked by radiant heat.

170 e amygdala (BLA) suppresses the radiant heat tail flick (TF) reflex in anesthetized rats.

171 measuring nociception with the radiant heat tail flick (TF) test.

172 ow that facilitation of a spinal nociceptive tail-flick (TF) reflex induced by stimulation in the NGC

173 Potentiation of analgesia (tail-flick [TF] test and hotplate test) was observed onl

174 Robust thermal hyperalgesia (tail-flick, TF, and Hargreaves tests) and mechanical all

175 tagonist N-allylnormetazocine (AD(50) in the tail-flick vs morphine assay = 0.3 mg/kg).